Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 5, 2013, Pages

  Sode, Birgitte F ^a,b,e   Allin, Kristine H ^a,e   Dahl, Morten ^c,e   Gyntelberg, Finn ^d,e   Nordestgaard, Boørge G ^a,d,e  

^a Department of Clinical Biochemistry ^*  (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 84875134556     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121636     Document Type: Article

References (34)

1. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011; 377: 383-92.
2. Trégouët DA, Heath S, Saut N, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009; 113: 5298-303.
3. Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a metaanalysis of the literature. Semin Thromb Hemost 2012;38:535-48.
4. Jick H, Slone D, Westerholm B, et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969; 1: 539-42.
5. Medalie JH, Levene C, Papier C, et al. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. N Engl J Med 1971;285:1348-53.
6. Talbot S, Wakley EJ, Langman MJ. A19 A29 B, and O bloodgroups, Lewis blood-groups, and serum triglyceride and cholesterol concentrations in patients with venous thromboembolic disease. Lancet 1972;1:1152-4.
7. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: A biologic function after all? Transfusion 2006;46:1836-44.
8. O'Donnell J, Boulton FE, Manning RA, et al. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002;22:335-41.
9. Orstavik KH, Magnus P, Reisner H, et al. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985;37:89-101.
10. Orstavik KH. Genetics of plasma concentration of von Willebrand factor. Folia Haematol Int Mag Klin Morphol Blutforsch 1990; 117:527-31.
11. Shima M, Fujimura Y, Nishiyama T, et al. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995;68:236-40.
12. Barbalic M, Dupuis J, Dehghan A, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 2010;19:1863-72.
13. Chung CM, Wang RY, Chen JW, et al. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J 2010; 10: 537-44.
14. Paterson AD, Lopes-Virella MF, Waggott D, et al. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol 2009;29:1958-67.
15. Qi L, Cornelis MC, Kraft P, et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of typediabetes. Hum Mol Genet 2010;19:1856-62.
16. Teupser D, Baber R, Ceglarek U, et al. Genetic regulation of serum phytosterol levels and risk of coronary artery disease. Circ Cardiovasc Genet 2010;3:331-9.
17. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
18. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999;99:999-1004.
19. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367:651-8.
20. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
21. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
22. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010;30:1672-8.
23. ABOblood.com. ABO Blood types reported racial and ethnic distribution. Available: www.aboblood.com (accessed 2012 Nov. 28).
24. Juul K, Tybjaerg-Hansen A, Schnohr P, et al. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004;140:330-7.
25. Weischer M, Juul K, Zacho J, et al. Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis 2010;208:480-3.
26. Ohira T, Cushman M, Tsai MY, et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007;5:1455-61.
27. Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008;168:1678-83.
28. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
29. Nossent AY, VAN Marion V, VAN Tilburg NH, et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006;4:2556-62.
30. Oriol R, Mollicone R, Coullin P, et al. Genetic regulation of the expression of ABH and Lewis antigens in tissues. APMIS Suppl 1992; 27:28-38.
31. Wu O, Bayoumi N, Vickers MA, et al. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008;6:62-9.
32. Franco RF, Trip MD, ten Cate H, et al. The 20210 G->A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104: 50-4.
33. Juul K, Tybjaerg-Hansen A, Marklund S, et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 2004; 109:59-65.
34. Madsen M, Davidsen M, Rasmussen S, et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-30.